

# **Certificate of Analysis**

Print Date: Sep 23<sup>rd</sup> 2019

www.tocris.com

Product Name: B 973B Catalog No.: 6764 Batch No.: 1

CAS Number: 2244989-34-0

IUPAC Name: 3,4-Difluoro-*N*-[(1S)-1-[6-[4-(2-pyridinyl)-1-piperazinyl]-2-pyrazinyl]ethyl]benzenepropanamide

#### 1. PHYSICAL AND CHEMICAL PROPERTIES

**Batch Molecular Formula:**  $C_{24}H_{26}F_2N_6O$ 

**Batch Molecular Weight:** 452.5

Physical Appearance: Off White solid
Solubility: DMSO to 100 mM

ethanol to 50 mM

1eq. HCl to 20 mM with gentle warming

Storage: Store at -20°C

**Batch Molecular Structure:** 

## 2. ANALYTICAL DATA

**TLC:**  $R_f = 0.5$  (Dichloromethane:Methanol [9:1])

HPLC: Shows 99.9% purity
Chiral HPLC: Shows 99.9% purity

<sup>1</sup>H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Microanalysis: Carbon Hydrogen Nitrogen

Theoretical 63.7 5.79 18.57 Found 63.69 5.76 18.48



# **Product Information**

Print Date: Sep 23<sup>rd</sup> 2019

www.tocris.com

Product Name: B 973B Catalog No.: 6764 Batch No.: 1

CAS Number: 2244989-34-0

IUPAC Name: 3,4-Difluoro-*N*-[(1S)-1-[6-[4-(2-pyridinyl)-1-piperazinyl]-2-pyrazinyl]ethyl]benzenepropanamide

#### **Description:**

Positive allosteric modulator of  $\alpha 7$  nAChRs (EC<sub>50</sub> ~0.3  $\mu$ M); active enantiomer. Increases potency of acetylcholine (EC<sub>50</sub> values are 0.007 mM and 0.3 mM in the presence and absence of B 937B, respectively). Potentiates peak acetylcholine-induced currents 6-fold relative to maximal acetylcholine, and slows channel desensitization, resulting in a 6900-fold increase in charge transfer. Decreases paw edema in vivo. Analgesic.

#### **Physical and Chemical Properties:**

Batch Molecular Formula:  $C_{24}H_{26}F_2N_6O$ 

Batch Molecular Weight: 452.5 Physical Appearance: Off White solid

**Minimum Purity:** >98%

#### **Batch Molecular Structure:**

Storage: Store at -20°C

### Solubility & Usage Info:

DMSO to 100 mM ethanol to 50 mM

1eq. HCl to 20 mM with gentle warming

#### Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

#### References:

**Quadri** *et al* (2019) Macroscopic and microscopic activation of a7 nicotinic acetylcholine receptors by the structurally unrelated allosteric agonist-positive allosteric modulators (ago-PAMs) B-973B and GAT107. Mol.Pharmacol. *95* 43. PMID: 30348894.

**Garai** *et al* (2018) B-973, a novel α7 nAChR Ago-PAM: racemic and asymmetric synthesis, electrophysiological studies, and *in vivo* evaluation. ACS Med.Chem.Lett. **9** 1144. PMID: 30429960.

**Post-Munson** *et al* (2017) B-973, a novel piperazine positive allosteric modulator of the  $\alpha$ 7 nicotinic acetylcholine receptor. Eur.J.Pharmacol. *15* 799. PMID: 28132910.